Cosmetic Ingredient Use Under Feinstein Bill; Where Does CIR Come In?
This article was originally published in The Rose Sheet
Whereas previous industry-backed legislation would have made final Cosmetic Ingredient Review safety determinations de facto FDA requirements unless the agency concluded differently, CIR would play a less conspicuous role in national cosmetics oversight under the proposed Personal Care Products Safety Act. Meanwhile, manufacturers would be required to file ingredient statements with FDA and attest to product safety, with opportunities for FDA to rebut their assertions and even suspend their distribution activities.
You may also be interested in...
Under the draft FDA Cosmetic Safety and Modernization Act, a product could be deemed adulterated "regardless of whether it is known which particular substance or substances may render the cosmetic injurious." EAS Consulting Group's John Bailey offers his perspective on the provision and the overall bill in an exchange with the Rose Sheet.
Lillian Gill, director of the Cosmetic Ingredient Review, helped to bolster CIR’s international reputation during her four-year stint leading the group. CIR’s profile has risen as a result of her leadership, openness to outside stakeholder input and increased public interest in cosmetic ingredients’ safety overall.
The Personal Care Products Council has a vision for marrying the Cosmetic Ingredient Review’s expertise with FDA’s authority, which it hopes to package into reform legislation expected this year. While FDA has balked at formalizing CIR’s role under previous proposals, this one was inspired by a third-party review program for medical devices, making it potentially more palatable to the agency and lawmakers.